New accounting (net revenues and EBITA focus) is a big pro, but growth remains muted and FCF weak, adj. EBITA -8-17%. High/risk reward BUY remains, TP SEK 16 (18).
9% organic growth adjusting for FX (vs cons 20%) Margin beat puts adj. EBITDA +1%/+2% vs cons/ABGe Est. down ~5%, share -5-10% as it is priced for growth
We reduce H2e org growth to 17% amid macro (20-21%) Margins still on the rise as synergies kick in steadily Adj. EBITDA -5-6%, TP to SEK 130 (150); BUY
Tough comp on org growth – we have 18% in Q2e (unch) Double-digit org growth, profitable and low leverage… …at an attractive valuation, we reiterate BUY
CFO Joakim Andersson to leave his position The PM is badly written, the CFO leaves on his choice Reaction (-11%) is understandable, but likely unjustified
Organic beat (28% vs 21%), adj. EBITDA -12% vs cons Guiding for EUR >40m synergies (from 40m) and earlier Estimates down ‘22e, up for ’23-24e, share slightly up
Estimates hold up well, 133% growth Q1e (20% organic) More visibility on synergies should give estimate support Adj. EBITDA +1%; BUY, TP 144 (146) on lower EURSEK
Solid organic growth story (36% in ‘21, 20% in ‘22e) 2022 estimates down on later synergies and one-offs High growth market leader; BUY - TP SEK 146 (168)
Momentum continues, lack of supply the main challenge Lucid acq. on track, synergies enable material upside Creating a clear market leader in the insights industry
Acquires largest competitor, Lucid, for SEK 9.2bn Doubles the size of Cint, raises growth & margin targets Highly accretive post-synergy multiples, share up ~20%